AAVXF — Abivax S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1956827 ·
France
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-09-21
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -84,110,000 | -117,433,000 | 462,209,000 | 387,992,000 | 95,942,000 |
| Mar 2026 | 0 | — | -56,229,000 | -48,468,000 | 547,142,000 | 477,423,000 | 117,548,000 |
| Dec 2025 | 0 | — | -71,648,000 | -81,960,000 | 584,341,000 | 516,685,000 | 129,136,000 |
| Sep 2025 | 0 | — | -80,712,000 | -153,358,000 | 652,052,000 | 589,703,000 | 140,814,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-178,371,000
Investing CF
$-8,780,000
Financing CF
$555,218,000
CapEx
$-204,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-4.30
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-764,311,000
Inventory
—
Receivables
$10,809,000
ST Investments
$14,128,000
EBIT TTM
$-300,576,000
Pretax Income TTM
$-326,124,000
Interest Exp TTM
$25,548,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,920,000
EBITDA
$-254,004,000
Free Cash Flow
$-114,471,872
Enterprise Value
$10,564,133,888
Total Cash
$491,552,000
Total Debt
$34,211,000
Shares Out
87,253,797
Trailing EPS
$-5.37
Book Value
$6.29
ROE
-157.1%
ROA
-44.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -246,056,000 | -336,102,000 | 584,341,000 | 129,136,000 | 455,205,000 | -161,129,000 |
| Dec 2024 | 0 | -172,984,000 | -176,242,000 | 205,228,000 | 164,644,000 | 40,584,000 | -154,072,000 |
| Dec 2023 | 0 | -127,377,000 | -147,740,000 | 327,062,000 | 131,052,000 | 196,010,000 | -97,130,000 |
| Dec 2022 | 0 | -51,205,000 | -60,740,000 | 75,544,000 | 68,355,000 | 7,189,000 | -53,936,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
ABIVAX Société Anonyme (ENXTPA:ABVX) Just Gave Investors Something To Think About
2026-09-27 09:09 · Yahoo
ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical Officers
2026-09-26 19:08 · Yahoo
ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?
2026-09-26 04:03 · Yahoo
Abivax Presents Business Updates and First Half 2026 Financial Results
2026-09-21 20:05 · Yahoo
4 Biotech Stocks to Watch as Potential Takeover Targets
2026-09-18 16:31 · Yahoo
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
2026-09-08 16:00 · Yahoo
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
2026-09-07 17:00 · Yahoo
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Ca
2026-08-04 07:00 · Yahoo
AbbVie Q2 Earnings Call Highlights
2026-07-31 15:04 · Yahoo
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
2026-07-30 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.